Company news

Femasys Inc. news in 2023

Femasys Inc.'s news releases, calls and decks from 2023, newest first.

View company

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

December 14, 2023

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

November 29, 2023

Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch

November 27, 2023

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

November 14, 2023

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update

November 13, 2023

Femasys Inc. EU MDR Final Audit Successfully Completed

October 25, 2023

Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons

October 24, 2023

Femasys Inc. Regains Compliance with Nasdaq Listing Requirements

October 10, 2023

Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine

October 3, 2023

Femasys Inc. MDSAP Surveillance Audit Successfully Completed

October 2, 2023

Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate

September 26, 2023

Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution

September 24, 2023

Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control

September 19, 2023

Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023

Femasys Inc. Obtains Medical Device Establishment License from Health Canada

August 30, 2023

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update

August 9, 2023

Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc

August 2, 2023

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control

July 26, 2023

Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women

June 25, 2023

Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences

June 14, 2023

Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

June 13, 2023

Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada

June 7, 2023

Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting

May 10, 2023

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023

May 10, 2023

Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 18, 2023

Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada

April 17, 2023

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update

March 29, 2023

Decks in 2023